Reference
- Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (London). 2017;49:1–12.
- Kiertiburanakul S, Wiboonchutikul S, Sukasem C, et al. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol. 2010;47:330–334.
- Kannangai R, David S, Sundaresan VC, et al. Frequency of transmitted drug resistance mutations among treatment-naïve HIV-1-infected individuals at a tertiary care centre in South India. Mol Diagn Ther. 2015;19:273–275.
- Katlama C, Clotet B, Mills A, et al. Short communication efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15:1045–1052.
- Lambert-Niclot S, Charpentier C, Storto A, et al. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy. J Antimicrob Chemother. 2014;69:1086–1089.
- Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res. 2010;8:194–198.
- Saravanan S, Kausalya B, Gomathi S, et al. Etravirine and rilpivirine drug resistance among HIV-1 subtype C infected children failing non-nucleoside reverse transcriptase inhibitor-based regimens in South India. AIDS Res Hum Retroviruses. 2017;33:567–574.
- Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;62:909–913.
- Asahchop EL, Wainberg MA, Sloan RD, et al. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012;56:5000–5008.